Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

890 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer.
Gonzalez-Ericsson PI, Wulfkhule JD, Gallagher RI, Sun X, Axelrod ML, Sheng Q, Luo N, Gomez H, Sanchez V, Sanders M, Pusztai L, Petricoin E, Blenman KRM, Balko JM; I-SPY2 Trial Team. Gonzalez-Ericsson PI, et al. Among authors: sheng q. Clin Cancer Res. 2021 Oct 1;27(19):5299-5306. doi: 10.1158/1078-0432.CCR-21-0607. Clin Cancer Res. 2021. PMID: 34315723 Free PMC article.
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.
Jovanović B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA. Jovanović B, et al. Among authors: sheng q. Clin Cancer Res. 2017 Aug 1;23(15):4035-4045. doi: 10.1158/1078-0432.CCR-16-3055. Epub 2017 Mar 7. Clin Cancer Res. 2017. PMID: 28270498 Free PMC article. Clinical Trial.
Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors.
Schafer JM, Lehmann BD, Gonzalez-Ericsson PI, Marshall CB, Beeler JS, Redman LN, Jin H, Sanchez V, Stubbs MC, Scherle P, Johnson KN, Sheng Q, Roland JT, Bauer JA, Shyr Y, Chakravarthy B, Mobley BC, Hiebert SW, Balko JM, Sanders ME, Liu PCC, Pietenpol JA. Schafer JM, et al. Among authors: sheng q. Sci Transl Med. 2020 Mar 11;12(534):eaaw8275. doi: 10.1126/scitranslmed.aaw8275. Sci Transl Med. 2020. PMID: 32161105 Free PMC article.
Combined Dusp4 and p53 loss with Dbf4 amplification drives tumorigenesis via cell cycle restriction and replication stress escape in breast cancer.
Hanna A, Nixon MJ, Estrada MV, Sanchez V, Sheng Q, Opalenik SR, Toren AL, Bauer J, Owens P, Mason FM, Cook RS, Sanders ME, Arteaga CL, Balko JM. Hanna A, et al. Among authors: sheng q. Breast Cancer Res. 2022 Jul 18;24(1):51. doi: 10.1186/s13058-022-01542-y. Breast Cancer Res. 2022. PMID: 35850776 Free PMC article.
Very low-level heteroplasmy mtDNA variations are inherited in humans.
Guo Y, Li CI, Sheng Q, Winther JF, Cai Q, Boice JD, Shyr Y. Guo Y, et al. Among authors: sheng q. J Genet Genomics. 2013 Dec 20;40(12):607-15. doi: 10.1016/j.jgg.2013.10.003. Epub 2013 Dec 8. J Genet Genomics. 2013. PMID: 24377867 Free PMC article.
890 results